Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

Conclusions The serum phosphorus-lowering effect of sucroferric oxyhydroxide was maintained over 1 year and associated with a lower pill burden, compared with sevelamer. Sucroferric oxyhydroxide was generally well tolerated long-term and there was no evidence of iron accumulation.

http://ndt.oxfordjournals.org/cgi/content/short/30/6/1037?rss=1

Source: Nephrology Dialysis Transplantation - May 20, 2015 Category: Urology & Nephrology Authors: Floege, J., Covic, A. C., Ketteler, M., Mann, J. F. E., Rastogi, A., Spinowitz, B., Chong, E. M. F., Gaillard, S., Lisk, L. J., Sprague, S. M., on behalf of the Sucroferric Oxyhydroxide Study Group Tags: Intra- and extracorporeal treatments of kidney failure Source Type: research